Skip to main content

Advertisement

Table 4 Incidence of hemoglobin levels ≥12 g/dL or ≥13 g/dL or rapid hemoglobin rises

From: Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

  Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
  Darbepoetin alfa 500 mcg Q3W
N = 176
Darbepoetin alfa 2.25 mcg/kg QW
N = 175
Darbepoetin alfa 500 mcg Q3W
N = 177
Darbepoetin alfa 2.25 mcg/kg QW
N = 177
Mean (SD) average weekly darbepoetin alfa dose, mcg/weeka 134 (36) 115 (41) 125 (34) 112 (43)
Hemoglobin threshold of ≥12 g/dL achieved at any time during the study, n (%)b 44 (31) 49 (34) 109 (66) 99 (63)
Hemoglobin threshold of ≥13 g/dL achieved at any time during the study, n (%)b 20 (11) 24 (14) 56 (32) 60 (34)
Dose withheld due to achievement of > 13 g/dL hemoglobin, n (%) 4 (2) 22 (13) 12 (7) 57 (32)
Rapid rise in hemoglobin, n (%)     
   ≥1 g/dL in 14 days 99 (56) 103 (59) 133 (75) 119 (67)
   ≥2 g/dL in 28 days 48 (27) 54 (31) 70 (40) 64 (36)
   Dose reduction due to rapid hemoglobin increasec, % (95% CI) 57 (49 to 64) 69 (61 to 75) 75 (67 to 81) 69 (62 to 76)
  1. Q3W = every three weeks; QW = weekly
  2. aExcluding withheld or missed doses.
  3. bHemoglobin measurements within 28 days of a RBC transfusion or whole blood transfusion were excluded.
  4. cA rapid hemoglobin increase sufficient to trigger dose reduction was defined as ≥1 g/dL hemoglobin rise in a 14-day window in the absence of a transfusion during the previous 14 days.